title: A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis.
abstract: OBJECTIVE
  To investigate if IV immunoglobulin (IVIG) treatment in the acute phase of optic neuritis (ON) could improve visual outcome and reduce MRI disease activity 6 months after onset of ON.
  
  
  METHODS
  Sixty-eight patients with ON were randomized within 4 weeks from onset of symptoms. Thirty-four patients were randomized to IVIG 0.4 g/kg body wt, and 34 patients were randomized to placebo. Infusions were given at days 0, 1, 2, 30, and 60. Contrast sensitivity, visual acuity, and color vision were measured at baseline and after 1 week, 1 month, and 6 months. Pattern reversal visual evoked potential studies and gadolinium-enhanced MRI were performed at baseline and after 1 and 6 months. Clinical relapses during follow-up were recorded.
  
  
  RESULTS
  There was no difference in the primary outcome, contrast sensitivity after 6 months, between patients randomized to treatment with IVIG or placebo. In addition, there was no significant difference in the secondary outcome measures, improvement in the visual function measures and MRI, at any time during follow-up. At baseline, a significantly higher number of patients in the IVIG group had one or more enhancing lesions on MRI and IVIG-treated patients had a significantly higher number of enhancing lesions on MRI than patients treated with placebo. No difference was found in number of patients with one or more enhancing lesions or number of enhancing lesions in subsequent scans between treatment groups. Number of relapses was equal in the two treatment groups during follow-up.
  
  
  CONCLUSIONS
  There was no effect of IV immunoglobulin (IVIG) on long-term visual function following acute optic neuritis, nor was there an effect of IVIG treatment in reducing latency on visual evoked potentials and thus preserving function of axons of the optic nerve.
authors.affiliation: MS Clinic, Department of Neurology, University of Copenhagen, Glostrup Hospital, Glostrup, Denmark. roeden@dadlnet.dk
authors.forename: H G
authors.initials: HG
authors.lastname: Roed
authors.forename: A
authors.initials: A
authors.lastname: Langkilde
authors.forename: F
authors.initials: F
authors.lastname: Sellebjerg
authors.forename: M
authors.initials: M
authors.lastname: Lauritzen
authors.forename: P
authors.initials: P
authors.lastname: Bang
authors.forename: A
authors.initials: A
authors.lastname: Mørup
authors.forename: J L
authors.initials: JL
authors.lastname: Frederiksen
mesh_terms: D000208:Acute Disease / Q000628:therapy; D000293:Adolescent; D000328:Adult; D015350:Contrast Sensitivity / Q000187:drug effects / Q000502:physiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009900:Optic Nerve / Q000187:drug effects* / Q000276:immunology* / Q000473:pathology; D009902:Optic Neuritis / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D015990:Placebo Effect; D055502:Secondary Prevention; D017211:Treatment Failure; D014792:Visual Acuity / Q000187:drug effects / Q000502:physiology
chemical_list: D016756:Immunoglobulins, Intravenous